Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.21 - $0.43 $11,031 - $22,588
-52,532 Reduced 13.43%
338,733 $74,000
Q2 2023

Aug 14, 2023

BUY
$0.55 - $1.26 $215,195 - $492,993
391,265 New
391,265 $273,000

Others Institutions Holding EIGR

About Eiger BioPharmaceuticals, Inc.


  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $490M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Rbf Capital, LLC Portfolio

Follow Rbf Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rbf Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rbf Capital, LLC with notifications on news.